<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841241</url>
  </required_header>
  <id_info>
    <org_study_id>1050147</org_study_id>
    <nct_id>NCT02841241</nct_id>
  </id_info>
  <brief_title>Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia</brief_title>
  <acronym>ECASSS-R</acronym>
  <official_title>Esmolol to Control Adrenergic Storm in Septic Shock - Roll-in</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm, &quot;roll-in&quot; study of esmolol infusion for patients with
      septic shock with persistent tachycardia after adequate intravenous volume expansion. The
      study will evaluate the adequacy and efficiency of study protocols for the anticipated, main
      ECASSS study, which will have a separate entry in clinicaltrials.gov.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      To evaluate the adequacy and efficiency of study protocols for the anticipated, randomized,
      controlled ECASSS study. The primary clinical outcome is organ-failure free days at 28 days,
      with multiple secondary outcomes, including those relevant to function of and compliance with
      the study protocols.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ-failure-free Days</measure>
    <time_frame>Day 28</time_frame>
    <description>As of day 28, the number of calendar days on which the patient receives none of (a) vasopressor therapy, (b) mechanical ventilation, or (c) renal replacement therapy. If the patients dies on or before day 28, they have -1 organ-failure-free days.
The resulting point-based score combines the probability of death and the number of days without organ failure.
Score of -1 = Death before day 28 (Lowest Score). Score of 28 = Patient has been successful at going 28 without any vasopressor therapy/mechanical ventilation/renal replacement therapy (Highest Score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Serum High-sensitivity Troponin</measure>
    <time_frame>Troponin is measured on day 0 and day 1 (first day of esmolol infusion is day 0)</time_frame>
    <description>Measured after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Global Longitudinal Strain at 24 Hours</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Heart Block</measure>
    <time_frame>for duration of esmolol infusion, an expected average of 2 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Compliance With Final Safety Check</measure>
    <time_frame>Day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage Hourly Checks During Which Protocol Compliance Was Observed</measure>
    <time_frame>for duration of esmolol infusion, an expected average of 2 days</time_frame>
    <description>For the esmolol titration protocol, each hour (the closest value of heart rate to the hour) during the esmolol infusion will be determined to be &quot;in range&quot; or &quot;out of range,&quot; with 3bpm margin for compliance (i.e., heart rate 77 to 93bpm). The initiation and cessation of esmolol will also be included as a timepoint for evaluation of compliance. Protocol compliance is considered adequate where overall compliance on hourly checks is &gt;80%.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Intolerance to Esmolol Infusion at Any Given Rate</measure>
    <time_frame>duration of esmolol infusion (~2 days)</time_frame>
    <description>Patients who met a prespecified stop event for esmolol titration, suggesting intolerance to a given infusion rate.
Per protocol, study drug titration: &quot;The target heart rate is 85 bpm. Start study drug infusion at 20 mcg/kg/min, without bolus, if HR (heart rate) ≥ 100 bpm. If HR &gt;90 bpm and &lt;100 bpm, start study drug infusion at 10 mcg/kg/min, without bolus. Increase by 20 mcg/kg/min every 20 minutes as long as HR &gt; 90 bpm, to a maximum dose of 100 mcg/kg/min. If HR &lt; 80 bpm and &gt; 70 bpm, decrease infusion rate by 10 mcg/kg/min; if HR ≤ 70 bpm and &gt; 60 bpm, decrease infusion rate by 20 mcg/kg/min.&quot;</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol infusion</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>Brevibloc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Within 48 hours of admission to the ICU and septic shock (sepsis present at time of
             admission)

             a. Septic shock defined by consensus criteria as i. At least two systemic inflammatory
             response syndrome (SIRS) criteria ii. Suspected or documented infection iii. Receiving
             vasopressors to treat hypotension after at least 20 ml/kg intravenous crystalloid
             volume expansion

          3. Receiving vasopressors through a central venous catheter for more than 60 minutes.

          4. Arterial catheter in place or expected to be placed imminently.

          5. Heart rate &gt; 90/min while receiving vasopressors for more than 60 minutes.

          6. Adequately volume expanded, as manifest by any of the following, performed as part of
             routine clinical care (i.e., no study procedures will be performed before signed
             consent). If none of these measures are clinically available, the clinical attending
             must confirm that volume expansion is adequate. (After enrollment, a final safety
             check will confirm the adequacy of volume expansion.)

               1. Central venous pressure (CVP) &gt; 15 mm Hg.

               2. Negative Passive-Leg Raise (PLR) maneuver (&lt;10% increase in cardiac output after
                  PLR).

               3. No cardiac output response (&lt;10% increase) after rapid infusion (&lt;5 min) of 250
                  ml of IV crystalloid, i.e., a graded volume expansion challenge (GVEC).

               4. For patients who happen to be breathing passively on a positive pressure
                  mechanical ventilator delivering at least 8 ml/kg tidal volumes and in normal
                  sinus rhythm, stroke volume variability &lt;10% (such patients are acknowledged to
                  be uncommon; the protocol does not recommend or require the induction of passive
                  breathing).

        Exclusion Criteria:

          1. Lack of informed consent.

          2. Currently receiving ECMO (extracorporeal membrane oxygenation).

          3. Known pregnancy or nursing.

          4. Patient is a prisoner.

          5. Patient on hospice (or equivalent comfort care approach) at or before the time of
             enrollment.

          6. Known or current atrial fibrillation.

          7. Previously enrolled in the trial.

          8. Known allergy to esmolol or vehicle

          9. Receipt of nodal blocking agents within three half lives

         10. Hemoglobin &lt; 7 gm/dl.

         11. Cardiac arrest within 24 hours.

         12. Pulmonary hypertension (moderate or severe), from documented history of prior right
             heart catheterization or current evidence on TTE (transthoracic echocardiography) of
             any of the following

               -  mPAP (mean pulmonary artery pressure) ≥ 35 mmHg

               -  SPAP (systolic pulmonary artery pressure)≥ 60 mmHg

         13. Cardiovascular collapse, as manifested by inability to achieve a MAP (mean arterial
             pressure) of 65 mmHg with vasopressor therapy.

         14. Cardiogenic shock, as defined by any of the following

               -  Cardiac index ≤ 2 L/min/m2

               -  Ejection fraction ≤ 25%

               -  ScvO2 ≤ 60%

               -  Current infusion of any dose of dobutamine, milrinone, or dopamine

               -  Current infusion of epinephrine for clinically diagnosed cardiogenic shock

         15. Significant atrioventricular dysfunction

               -  Sick sinus syndrome

               -  PR interval (time from onset of P wave to start of QRS complex) &gt; 200 msec

               -  Current evidence or prior history of Grade 2 or Grade 3 heart block

               -  Pacemaker or plans to place a pacemaker

         16. Pheochromocytoma or status asthmaticus

         17. Receiving clonidine, guanfacine, or moxonidine

         18. Hemoglobin &lt; 7 gm/dl

         19. Cardiovascular collapse (failure to achieve MAP of 65mmHg)

         20. Cardiac arrest within 24 hours

         21. Worse than moderate aortic stenosis

             • Known aortic stenosis, with any of (1) mean gradient ≥ 40 mmHg OR (2) maximum
             gradient ≥ 60mmHg OR (3) aortic valve area ≤ 1.0cm2 OR (4) aortic valve area index ≤
             0.85cm2/m2 body surface area.

         22. Worse than mild mitral stenosis • Known mitral stenosis, with any of (1) valve area ≤
             1.5 cm2 OR mean gradient ≥ 5 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Brown, MD,MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intermountain Medical Center and Intermountain Clinics</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pilotfeasibilitystudies.biomedcentral.com/articles/10.1186/s40814-018-0321-5</url>
    <description>Esmolol infusion in patients with septic shock and tachycardia: a prospective, single-arm, feasibility study</description>
  </link>
  <reference>
    <citation>Rudiger A, Singer M. The heart in sepsis: from basic mechanisms to clinical management. Curr Vasc Pharmacol. 2013 Mar 1;11(2):187-95. Review.</citation>
    <PMID>23506497</PMID>
  </reference>
  <reference>
    <citation>Novotny NM, Lahm T, Markel TA, Crisostomo PR, Wang M, Wang Y, Ray R, Tan J, Al-Azzawi D, Meldrum DR. beta-Blockers in sepsis: reexamining the evidence. Shock. 2009 Feb;31(2):113-9. doi: 10.1097/SHK.0b013e318180ffb6. Review.</citation>
    <PMID>18636043</PMID>
  </reference>
  <reference>
    <citation>Oberbeck R, Kobbe P. Beta-adrenergic antagonists: indications and potential immunomodulatory side effects in the critically ill. Curr Med Chem. 2009;16(9):1082-90. Review.</citation>
    <PMID>19275613</PMID>
  </reference>
  <reference>
    <citation>Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013 Oct 23;310(16):1683-91. doi: 10.1001/jama.2013.278477.</citation>
    <PMID>24108526</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <results_first_submitted>August 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2019</results_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esmolol</keyword>
  <keyword>adrenergic storm</keyword>
  <keyword>septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02841241/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Esmolol</title>
          <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esmolol</title>
          <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admission APACHE (Acute Physiologic Assessment and Chronic Health Evaluation) II</title>
          <description>&quot;estimates ICU mortality based on a number of laboratory values and patient signs taking both acute and chronic disease into account&quot;; score is from 0-100, with 0 being a low risk of mortality and 35-100 being a high risk</description>
          <units>Units on a scale (0-100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Organ-failure-free Days</title>
        <description>As of day 28, the number of calendar days on which the patient receives none of (a) vasopressor therapy, (b) mechanical ventilation, or (c) renal replacement therapy. If the patients dies on or before day 28, they have -1 organ-failure-free days.
The resulting point-based score combines the probability of death and the number of days without organ failure.
Score of -1 = Death before day 28 (Lowest Score). Score of 28 = Patient has been successful at going 28 without any vasopressor therapy/mechanical ventilation/renal replacement therapy (Highest Score)</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Organ-failure-free Days</title>
          <description>As of day 28, the number of calendar days on which the patient receives none of (a) vasopressor therapy, (b) mechanical ventilation, or (c) renal replacement therapy. If the patients dies on or before day 28, they have -1 organ-failure-free days.
The resulting point-based score combines the probability of death and the number of days without organ failure.
Score of -1 = Death before day 28 (Lowest Score). Score of 28 = Patient has been successful at going 28 without any vasopressor therapy/mechanical ventilation/renal replacement therapy (Highest Score)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="24.5" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Serum High-sensitivity Troponin</title>
        <description>Measured after enrollment.</description>
        <time_frame>Troponin is measured on day 0 and day 1 (first day of esmolol infusion is day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum High-sensitivity Troponin</title>
          <description>Measured after enrollment.</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.12" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Global Longitudinal Strain at 24 Hours</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Global Longitudinal Strain at 24 Hours</title>
          <units>Percentage of myocardial shortening (%)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" lower_limit="-20.1" upper_limit="-13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Heart Block</title>
        <time_frame>for duration of esmolol infusion, an expected average of 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Heart Block</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Compliance With Final Safety Check</title>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Compliance With Final Safety Check</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage Hourly Checks During Which Protocol Compliance Was Observed</title>
        <description>For the esmolol titration protocol, each hour (the closest value of heart rate to the hour) during the esmolol infusion will be determined to be &quot;in range&quot; or &quot;out of range,&quot; with 3bpm margin for compliance (i.e., heart rate 77 to 93bpm). The initiation and cessation of esmolol will also be included as a timepoint for evaluation of compliance. Protocol compliance is considered adequate where overall compliance on hourly checks is &gt;80%.</description>
        <time_frame>for duration of esmolol infusion, an expected average of 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Hourly Checks During Which Protocol Compliance Was Observed</title>
          <description>For the esmolol titration protocol, each hour (the closest value of heart rate to the hour) during the esmolol infusion will be determined to be &quot;in range&quot; or &quot;out of range,&quot; with 3bpm margin for compliance (i.e., heart rate 77 to 93bpm). The initiation and cessation of esmolol will also be included as a timepoint for evaluation of compliance. Protocol compliance is considered adequate where overall compliance on hourly checks is &gt;80%.</description>
          <units>Percentage of hourly checks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Intolerance to Esmolol Infusion at Any Given Rate</title>
        <description>Patients who met a prespecified stop event for esmolol titration, suggesting intolerance to a given infusion rate.
Per protocol, study drug titration: &quot;The target heart rate is 85 bpm. Start study drug infusion at 20 mcg/kg/min, without bolus, if HR (heart rate) ≥ 100 bpm. If HR &gt;90 bpm and &lt;100 bpm, start study drug infusion at 10 mcg/kg/min, without bolus. Increase by 20 mcg/kg/min every 20 minutes as long as HR &gt; 90 bpm, to a maximum dose of 100 mcg/kg/min. If HR &lt; 80 bpm and &gt; 70 bpm, decrease infusion rate by 10 mcg/kg/min; if HR ≤ 70 bpm and &gt; 60 bpm, decrease infusion rate by 20 mcg/kg/min.&quot;</description>
        <time_frame>duration of esmolol infusion (~2 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intolerance to Esmolol Infusion at Any Given Rate</title>
          <description>Patients who met a prespecified stop event for esmolol titration, suggesting intolerance to a given infusion rate.
Per protocol, study drug titration: &quot;The target heart rate is 85 bpm. Start study drug infusion at 20 mcg/kg/min, without bolus, if HR (heart rate) ≥ 100 bpm. If HR &gt;90 bpm and &lt;100 bpm, start study drug infusion at 10 mcg/kg/min, without bolus. Increase by 20 mcg/kg/min every 20 minutes as long as HR &gt; 90 bpm, to a maximum dose of 100 mcg/kg/min. If HR &lt; 80 bpm and &gt; 70 bpm, decrease infusion rate by 10 mcg/kg/min; if HR ≤ 70 bpm and &gt; 60 bpm, decrease infusion rate by 20 mcg/kg/min.&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of esmolol infusion (approximately 2 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Esmolol</title>
          <description>Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
Esmolol: Esmolol infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Office of Research</name_or_title>
      <organization>Intermountain Medical Center</organization>
      <phone>8015077000</phone>
      <email>officeofresearch@imail.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

